| 米 婷,尚 东,李 媛,唐广林,史柳嫣,摆念祖.血必净联合乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效[J].,2017,17(33):6544-6548 |
| 血必净联合乌司他丁治疗慢性阻塞性肺疾病急性加重期的临床疗效 |
| Clinical Efficacy of Xuebijing Combined with Ulinastatin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
| 投稿时间：2017-06-06 修订日期：2017-06-29 |
| DOI：10.13241/j.cnki.pmb.2017.33.033 |
| 中文关键词: 血必净 乌司他丁 慢性阻塞性肺疾病 急性加重期 |
| 英文关键词: Xuebijing Ulinastatin Chronic obstructive pulmonary disease Acute exacerbation |
| 基金项目: |
|
| 摘要点击次数: 45 |
| 全文下载次数: 51 |
| 中文摘要: |
| 摘要 目的：探讨血必净联合乌司他丁治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法：将2013年4月~2016年7月80例AECOPD患者随机分为三组，在常规治疗的基础上，A组(n=22)静滴血必净注射液50 mL，2次/d；B组(n=26)静滴乌司他丁注射液10 U，2次/d；C组(n=32)静滴血必净注射液50 mL与乌司他丁注射液10U，2次/d。比较三组治疗前后的临床症状评分、肺功能、血气分析、血清细胞因子及临床疗效。结果：治疗后，三组临床症状评分、PaCO2、血清IL-6、TNF-α水平均较治疗前明显降低(P＜0.05)，C组临床症状评分、PaCO2、血清IL-6、TNF-α水平明显低于A、B组(P＜0.05)，FEV1、FEV1/FVC、PaO2、临床控制率均明显高于A、B组(P＜0.05)，A、B组以上指标比较差异均无统计学意义(P＞0.05)。治疗过程中，三组均未见明显的不良反应。结论：血必净联合乌司他丁治疗AECOPD可有效缓解临床症状，改善肺功能，抑制炎症因子，疗效优于单药治疗。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect ofXuebijing combined with Ulinastatin in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods: 80 patients with AECOPD were randomly divided into three groups from April 2013 to July 2016 on the basis of conventional treatment, the group A (n=22) was treated with Xuebijing injection 50ml, twice per day; the group B (n=26) was treated with Ulinastatin injection 10U, twice per day; the group C(n=32) was treated with Xuebijing injection 50 mL and Ulinastatin injection 10U, twice per day. The clinical symptom score, lung function, blood gas analysis，serum inflammatory factors levels before and after treatment and clinical efficacy were compared among three groups. Results: After treatment, the clinical symptom scores of group C was significantly lower than that of the group A and B (P<0.05); the FEVl %, FEV l/FVC, PaO2 and PaCO2 of group C were significantly better than those of group A and B(P<0.05); the serum levels of IL-6 and TNF-α of group C were significantly lower than those of group A and B (P<0.05); the clinical control rate of the group C was significantly higher than that of group A and group B(P<0.05). There was no significant difference in the above index between group A and group B (P>0.05). Conclusion: Xuebijing combined with ulinastatin can effectively relieve clinical symptoms, improve lung function and inhibit inflammatory factors in the treatment of AE- COPD, the curative effect is better than single drug treatment. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
